Growth Metrics

Ionis Pharmaceuticals (IONS) Liabilities and Shareholders Equity (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Liabilities and Shareholders Equity data on record, last reported at $3.0 billion in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 1.56% year-over-year to $3.0 billion; the TTM value through Dec 2025 reached $8.8 billion, down 23.47%, while the annual FY2024 figure was $3.0 billion, 0.45% changed from the prior year.
  • Liabilities and Shareholders Equity reached $3.0 billion in Q3 2025 per IONS's latest filing, up from $3.0 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $3.1 billion in Q3 2024 and bottomed at $2.2 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $2.7 billion, with a median of $2.8 billion recorded in 2024.
  • Peak YoY movement for Liabilities and Shareholders Equity: dropped 27.25% in 2021, then rose 21.14% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.6 billion in 2021, then decreased by 2.98% to $2.5 billion in 2022, then grew by 18.0% to $3.0 billion in 2023, then rose by 0.45% to $3.0 billion in 2024, then increased by 0.98% to $3.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $3.0 billion in Q3 2025, $3.0 billion in Q2 2025, and $2.8 billion in Q1 2025.